We provide total solutions that enhance the value of life.
Recombinant Protein Research
Recombinant protein therapeutics utilize genetic engineering to efficiently express and purify therapeutic proteins in recombinant form for the treatment of diseases.
In the field of recombinant protein therapeutics, Daewoong Pharmaceutical has built technical expertise and research know‑how based on multiple approved products and continues to develop safe and highly effective biologics through advanced protein engineering and production platforms.
We are also strengthening future growth potential through research into next‑generation therapeutics.
Recombinant Protein‑Based Biologics R&D
Developing growth factor therapies and musculoskeletal disease treatments using therapeutic proteins such as EGF (epidermal growth factor), hGH (human growth hormone), EPO (erythropoietin), and BMP‑2 (bone morphogenetic protein‑2), building technological competitiveness in these areas.
Expanding Research Areas and Strengthening Future Growth
Expanding into new therapeutic areas, including metabolic diseases, sarcopenia, obesity, and aging‑related conditions.
Strengthening future competitiveness through the development of next‑generation biomaterials, such as skin regeneration and hemostatic materials.
Focus areas
Musculoskeletal Disorders
Bone formation and cartilage regeneration‑based therapies
Pain relief and functional recovery
Spinal disorders
Joint pain relief
Sarcopenia
Regenerative Medicine
Therapies based on cell regeneration
Promoting the recovery of refractory wounds and skin regeneration
Skin regeneration and Wound healing
Diabetic foot ulcers
Skin boosters
Metabolic Disorders
Hormone‑based therapies for metabolic diseases
Improving obesity and systemic metabolism
Human Growth Hormone
Obesity
Musculoskeletal Disorders
Bone formation and cartilage regeneration‑based therapies
Pain relief and functional recovery
Spinal disorders
Joint pain relief
Sarcopenia
Regenerative Medicine
Therapies based on cell regeneration
Promoting the recovery of refractory wounds and skin regeneration
Skin regeneration and Wound healing
Diabetic foot ulcers
Skin boosters
Metabolic Disorders
Hormone‑based therapies for metabolic diseases
Improving obesity and systemic metabolism
Human Growth Hormone
Obesity
Core Competency
Defining new paradigms in treatment through advanced technology and differentiated research
Core Competency 01
End-to-End Biopharmaceutical Development Capabilities
We possess the capabilities to execute the full spectrum of biopharmaceutical development—from research planning and process development to analytical technologies and commercialization. We also have extensive experience in obtaining regulatory approvals for various biopharmaceutical products in compliance with global regulatory requirements.
01 Integrated R&D Platform for Recombinant Protein-Based Therapeutics
- One-stop execution from initial project planning to candidate optimization
- Reduced development timelines through in-house capabilities in cell culture, purification, formulation development, and analytical method development
02 Expertise in Global Regulatory Strategy and Product Approval
- Development strategies aligned with regulatory requirements of agencies such as the FDA and PMDA
- Strong capabilities in regulatory documentation and review response based on extensive product approval experience
Core Competency 02
Scale‑Up Expertise
We possess a recombinant protein production scale‑up platform that integrates Lab–Pilot–Commercial stages based on both E. coli and mammalian cell systems.
01 Expansion Capabilities Based on Pilot-Scale Facilities
- In‑house capabilities from lab scale to pilot‑scale production using E. coli and mammalian cell systems
- Ability to produce nonclinical materials through pilot production and conduct scale‑up studies toward commercial manufacturing
- Verification of process stability and reproducibility across multiple production scales
02 Scale‑Up Expertise for Commercial Manufacturing
- A 1,000 L GMP manufacturing facility within the group enables integration across the Lab–Pilot–Commercial continuum
- Establishment of process conditions to improve production efficiency and ensure consistent quality
- Strengthening manufacturing competitiveness through accumulated experience in commercial‑scale scale‑up